

Resource Summary Report

Generated by [RRID](#) on Sep 4, 2026

888-mel

RRID:CVCL_4632

Type: Cell Line

Proper Citation

RRID:CVCL_4632

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_4632

Proper Citation: RRID:CVCL_4632

Description: Cell line 888-mel is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Melanoma

Defining Citation: [PMID:8027550](#), [PMID:8081556](#), [PMID:8537970](#), [PMID:9598804](#), [PMID:9670966](#), [PMID:10048982](#), [PMID:10754339](#), [PMID:15467732](#), [PMID:16470173](#), [PMID:18172304](#), [PMID:25485619](#), [PMID:25502142](#), [PMID:25538140](#)

Comments: Population: Caucasian., From: Rosenberg, Steven A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: 888-mel

Synonyms: 888-MEL, 888 mel, 888mel, 888MEL, 888, Mel888, mel888, MG-888

Cross References: BTO:BTO_0002950, EFO:EFO_0006531, ArrayExpress:E-MTAB-2706, cancercellines:CVCL_4632, CGH-DB:9308-4, Cosmic:876679, Cosmic:877281, Cosmic:905221, Cosmic:1042621, Cosmic:1238108, Cosmic:1303045, EGA:EGAS00001000610, GEO:GSM206439, GEO:GSM218046, GEO:GSM274691, GEO:GSM1092556, GEO:GSM1507930, PharmacDB:888mel_32_2019, Progenetix:CVCL_4632, Wikidata:Q54605471

ID: CVCL_4632

Record Creation Time: 20220427T215102+0000

Record Last Update: 20260904T021126+0000

Ratings and Alerts

No rating or validation information has been found for 888-mel.

No alerts have been found for 888-mel.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Kobayashi Y, et al. (2025) IgSF11-RAP1 signaling promotes cell migration and invasion of cutaneous melanoma. Cell communication and signaling : CCS, 23(1), 330.

Champagne J, et al. (2025) Adoptive T??cell therapy targeting an inducible and broadly shared product of aberrant mRNA translation. Immunity, 58(1), 247.

Eisenberg V, et al. (2024) Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells. Cancer immunology research, 12(10), 1380.

Kenski JCN, et al. (2023) An adverse tumor-protective effect of IDO1 inhibition. Cell reports. Medicine, 4(2), 100941.

Carcamo S, et al. (2022) Altered BAF occupancy and transcription factor dynamics in PBAF-deficient melanoma. Cell reports, 39(1), 110637.

Wilcock DJ, et al. (2022) Oxidative stress from DGAT1 oncoprotein inhibition in melanoma suppresses tumor growth when ROS defenses are also breached. Cell reports, 39(12), 110995.

Song K, et al. (2022) Plasticity of Extrachromosomal and Intrachromosomal BRAF Amplifications in Overcoming Targeted Therapy Dosage Challenges. Cancer discovery, 12(4), 1046.

Cui C, et al. (2021) Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis. Cell, 184(12), 3163.

Creelan BC, et al. (2021) Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nature medicine, 27(8), 1410.

Vredevoogd DW, et al. (2019) Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold. *Cell*, 178(3), 585.

Zingg D, et al. (2018) EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation. *Cancer cell*, 34(1), 69.

Wang L, et al. (2018) An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential. *Cell*, 173(6), 1413.